References due for review: February 2024
Anagrelide Summary Product Characteristics. 25 April 2019. European Medicines Agency. European public assessment report (EPAR) product information. Available at: https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=Anagrelide. Accessed: 7 Dec 2020.
Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, et al. A phase 2 study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol 2013;162(4):498-508.
Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Haematol 2012;87(2):175-182.
Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. Am J Haematol 2016;91(3):318-321.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood 2016;127:2391–2405.
Aspirin Summary Product Characteristics. 30 December 2019. Electric Medicines Compendium. Available at : https://www.medicines.org.uk/emc/product/5712/smpc. Accessed: 7 Dec 2020.
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer J 2018;8(2):15.
Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica 2018;103(1):51-60.
Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 2017;58:14-22.
Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 2015;5(11):e366.
Cervantes F, Isola IM, Alvarez-Larran A, Hernandez-Boluda JC, CorreaJG, Pereira A. Danazol therapy for the anaemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015;94(11):1791-1796.
Coltro G, Mannelli F, Guglielmelli P, Pacilli A, Bosi A, Vannucchi AM. A life-threatening ruxolitinib discontinuation syndrome. Am J Haematol 2017;92(8):833-838.
Eran Z, Zingariello M, Bochicchio MT, Bardelli C, Migliaccio AR. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its aetiology. F1000Res 2019;8:1662.
Fedratinib (Inrebic) Prescribing highlights. 16 August 2019. Food and Drug Administration (FDA). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf. Accessed: 11 January 2021.
Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukaemia 2012;26(4):716-719.
Gerds AT, Dao KH. Polycythaemia vera management and challenges in the community health setting. Oncology 2017;92(4):179-189.
Griesshammer M, Kiladjian, JJ, Besses C. Thromboembolic events in polycythaemia vera. Ann Haematol 2019; 98, 1071–1082.
Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, et al. Symptom burden and blood counts in patients with polycythaemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk 2019;19(9):579-584.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 2018;36:310–318.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-798.
Harrison C. When to initiate treatment in myelofibrosis. Clin Adv Hematol Oncol 2016;14(11):934-937.
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 2017;96(10):1653-1665.
Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. Ann Hematol 2020;99(6):1177-1191.
Hultcrantz M, Ravn Landtblom A, Andreasson B, Samuelsson J, Dickman PW, Kristinsson SY, et al. Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population-based study in Sweden. J Intern Med 2020;287(4):448-454.
Hydroxycarbamide Summary Product Characteristics. 9 October 2018. Electric Medicines Compendium. Available at https://www.medicines.org.uk/emc/product/254/smpc. Accessed: 7 Dec 2020.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N; Study Alliance Leukaemia (SAL). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Haematol Oncol 2016;9:18.
Kleman A, Singavi AK, Michaelis LC. Current challenges in the management of essential thrombocythemia. Clin Adv Hematol Oncol 2017;15(10):773-783.
Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: A systematic review and meta-analysis. Am J Haematol 2018;93(3):339-347.
Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F, et al. Cardiovascular risk in polycythaemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythaemia vera with cardiovascular risk factors? Oncol Res Treat 2020;43(10):526-530.
Mascarenhas J, Komrokji RS, Cavo M, Martino B, Niederwieser D, Reiter A, et al. Imetelstat is effective treatment for patients with intermediate- or high-risk myelofibrosis who have relapsed on or are refractory to Janus Kinase inhibitor therapy: Results of a phase 2 randomized study of two dose levels. Blood 2018;132(1): Abstract 685.
Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, et al. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies. Leukaemia and Lymphoma 2019;60(7):1789-1795.
McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica 2019;104(4):659-668.
McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol 2019;184(2):176-191.
Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and haematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 2017;123(3):449-458.
Mesa RA. The new NCCN guidelines for the management of myelofibrosis. Clin Adv Haematol Oncol 2017;15(3):193-195.
Mesa RA, Harrison CN. Fast Facts: Myeloproliferative Neoplasms. First ed, Oxford: S. Karger Publishers Ltd Oxford, 2019
National Institute for Health and Care Excellence (NICE) 2016. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. Technology appraisal guidance [TA386]. Published date: 23 March 2016. Available at: https://www.nice.org.uk/guidance/ta386. Accessed:
O’Sullivan JM, Harrison CN. Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol 2018;16(2):121-131.
Plo I, Marty C. Not just another kinase mutation! Blood 2019;134(26):2335-2237.
Qian CJ, Yao J, Si JM. Nuclear JAK2: form and function in cancer. Anat Rec(Hoboken) 2011;294(9):1446-1459.
Ruxolitinib (Jakavi) Summary Product Characteristics. 24 April 2017. European Medicines Agency (EMA). European public assessment report (EPAR) product information. Available at: https://www.ema.europa.eu/en/documents/product-information/jakavi. Accessed: 7 Dec 2020.
Schieber M, Crispino JD, Stein B. Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J 2019;9(9):74.
Song MK, Park BB, Uhm JE. Understanding Splenomegaly in Myelofibrosis: Association with
Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al; Infectious Diseases Working Party EBMT. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant 2020;55(1):126-136.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Haematol 2019;94(1):133-143.
Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 2018b;36(17):1769–1770.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukaemia 2014;28(7):1472-1477.
Tefferi A, Vannucchi AM, Barbui T. Polycythaemia vera treatment algorithm 2018. Blood Cancer J 2018;8(1):3.Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Haematol 2018a;93(12):1551-1560.
Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Haematol 2014;89(6):581-587.
Trifa AP, Cucuianu A, Popp RA. Familial essential thrombocythemia associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter. Case Rep Haematol. 2014;2014:841787.
Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2018;93(12):1551-1560.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;100(9):1139-1145.
Yogarajah M, Tefferi A. Leukaemic transformation in myeloproliferative neoplasms: A literature review on risk, characteristics, and outcome. Mayo Clin Proc 2017;92(7):1118-1128.Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica 2016;101(6):660-671.
Zubatiuk R, Aljawfi O, Garlington B, Ghosh R. Ligand-based virtual screening for discovery of JAK2 inhibitors. In: Proceedings from the 15th LACCEI International Multi-Conference for Engineering, Education, and Technology: “Global Partnerships for Development and Engineering Education”, 19-21 July 2017, Boca Raton Florida, United States.